Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $1.44 million versus the consensus estimate of $695.33 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.